跳至主要内容
临床试验/DRKS00007761
DRKS00007761已完成未知

High myopia: extended and longterm observation of pathologic myopia patients with the risk for developing a myopic CNV. - HELP

ovartis Pharma GmbH0 个研究点目标入组 152 人开始时间: 2015年2月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
152

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Male or female Caucasian patients = 18 years of age
  • -Diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using the following criteria:
  • Ocular ultrasonography or biometry demonstrating anterior-posterior elongation measurement = 26 mm
  • abnormal change in retinal tissue by SD-OCT that are attributed to be caused by high myopia as shown in Table 4-2 in the investigator’s discretion confirmed by the reading centre.
  • -BCVA = 0.05 decimal equivalent in the study eye

排除标准

  • -Use of any investigational drugs -excluding vitamins and minerals- at the time of enrolment, or within 30 days or 5 half-lives of enrolment, whichever is longer
  • -Patients with Diabetes mellitus of any grade
  • -Patients showing signs of AMD, e.g. drusen, characteristic changes in fundus (with shaping or extension of hemorrhages, fibrosis, exsudative areas) in either eye
  • -Acute neovascularization (CNV or iris neovascularization) and intra- or subretinal fluid in either eye at the time of enrolment
  • -History of inactive CNV in study eye. Inactive CNV of fellow eye is allowed if treatment was performed more than 12 months before enrolment
  • -Any anti-VEGF or Verteporfin treatment in study eye and anti-VEGF or Verteporfin treatment less than 12 months before enrolment in fellow eye
  • -History of systemic anti-VEGF therapy
  • -Cataract that would prevent an accurate measurement of the axial length of the study eye
  • -Presence of active infectious disease or intra-ocular inflammation in either eye at the time of enrolment (e.g. PIC, Uveitis)
  • -Ocular disorders that may confound interpretation of research project results, compromise visual acuity or require medical or surgical intervention during the observation period (including retinal detachment, cataract and pre-retinal membrane of the macula)
  • -Ocular disorders which may lead to an ophthalmic surgery within 5 years
  • -Further retinal disorders such as retinopathia pigmentosa/centralis, diabetic maculopathy or Marfan syndrome
  • -Patients with inability to comply with the research project or follow up procedures
  • -Research project personnel or first degree relatives of investigator(s)

研究者

发起方
ovartis Pharma GmbH

相似试验